All In Biotech

Drug Trial Radar · NCT07905560

A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.

A First-In-Human, Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Limited Duration Treatment, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SUN-0864 in Healthy Adult Participants and Participants Who Are Overweight and/or Obese, Otherwise Healthy

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Superluminal Medicines, Inc.Industry
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1, first-in-human study will evaluate the safety and tolerability of SUN-0864, how the body processes SUN-0864, and how SUN-0864 affects the body in healthy adults and otherwise healthy adults who are overweight or obese. The study includes four parts: Part 1, a single ascending dose (SAD) assessment in healthy adults; Part 2, a 28-day multiple ascending dose (MAD) assessment in overweight or obese adults; Part 3, a 12-week multiple-dose assessment in overweight or obese adults; and Part 4, an assessment comparing two formulations and evaluating the effect of food on SUN-0864 in healthy adults. Approximately 128 to 138 subjects will be randomized into this study. Dose escalation and selection of dose levels for later study parts will be guided by review of safety, tolerability, and available study data by a Safety Review Committee.

Conditions

  • Healthy Participants

Interventions

  • SUN-0864 or placeboDrug

    Single ascending dose of SUN-0864 or placebo (oral)

  • SUN-0864 or placeboDrug

    Multiple ascending dose of SUN-0864 or placebo (oral)

  • SUN-0864 or placeboDrug

    Multiple doses of SUN-0864 or placebo (oral)

  • SUN-0864 (Formulation 1) or SUN-0864 (Formulation 2)Drug

    SUN-0864 (oral) Dose level Formulation 1 (fasted) and Formulation 2 (fasted and fed)

  • PlaceboDrug

    Placebo (oral)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 1)Time frame: Baseline up to Follow-Up (From Day -28 (Screening) to Day 37 (FUP visit)
  2. Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 2)Time frame: From Day -28 (Screening) to Day 60 (FUP visit)
  3. Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 3)Time frame: From Day -28 (Screening) to Day 119 (FUP visit)
  4. Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 4)Time frame: From Day -28 (Screening) to Day 37 (FUP visit)
  5. Cmax measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
  6. Tmax measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
  7. t1/2 measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
  8. AUClast measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
  9. AUCinf measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
  10. AUC24 measurement of SUN-0864 in Part 4Time frame: up to 24 hours post-dose. Daily from Day 1 (Predose) to Day 3.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.